Efficiency, Safety, and Efficacy of High-Power Short-Duration Radiofrequency Ablation in Patients with Atrial Fibrillation

Table 3

Clinical efficiency and efficacy between the HPSD group and CAT group.

Study	Sample size/HPSD population	Power (W)	AF type	Clinical efficiency HPSD group vs. CAT group			Clinical efficacy HPSD group vs. CAT group			Ablation strategy
				Procedure time (min)	RF ablation time (min)	Fluoroscopy time (min)	First-round isolation (%)	Acute PV reconnection (%)	Long term AF recurrence rate (%)
Bunch et al. [21]	804/402	50	PAF and PsAF	104.3 ± 63.6 vs. 170.8 ± 59.2; ()	—	15.0 ± 8.4 vs. 20.1 ± 18.6; ()	—	—	12.9 vs. 16.2 () (1 year); 26.5 vs. 30.7 () (3 years)	PVI ± linear ablation
Vassallo et al. [24]	76/41	45–50	PAF and PsAF	106 ± 23vs148 ± 33.6; ()	31.8 ± 11.3 vs. 76.0 ± 33.3; ()	8.8 ± 6.6 vs. 8.5 ± 3.5; ()	—	—	17.07 vs. 31.42 () (1 year)	PVI
Okamatsu et al. [25]	60/20	40–50	PAF and PsAF	—	40 [28–63] vs. 84[272–93] ()	10 [IQR 8–11] vs. 10 [IQR 8–13] ()	85 vs. 55 ()	0 vs. 10 ()	0 vs. 5 () (6 months)	PVI ± CTI ± linear ablation ± CFAE ± SVCI
Berte et al. [26]	174/80	35–45	PAF and PsAF	82 ± 18 vs. 100 ± 22 ()	23±5 vs. 36 ± 11 ()	—	RPV: 83 vs. 84 (); LPV: 94 vs. 90 ()	—	18 vs. 17 () (6 months)	PVI ± CTI
Kottmaier et al. [27]	197/97	70	PAF	89.5 ± 23.9 vs. 111.15 ± 27.9; ()	12.4 ± 3.4 vs. 35.6 ± 12.1; ()	6.3 ± 3.9 vs. 6 ± 3.8 ()	—	—	18.9 vs. 34.9 () (1 year)	PVI
Pambrun et al. [29]	100/50	40–50	PAF	73.1 ± 18.2 vs. 107.4 ± 21.2 ()	13 ± 2.9 vs. 30.3 ± 8.8 ()	—	92 vs. 73 ()	2 vs. 17 ()	—	PVI
Castrejón-Castrejón et al. [30]	95/48	50–60	PAF and PsAF	106 ± 33 vs. 120 ± 45 ()	17±3 vs. 34 ± 7 ()	7 ± 6 vs. 30 ± 16 ()	57 vs. 39 ()	5 vs. 8 ()	—	PVI ± CTI ± linear ablation
Ejima et al. [31]	120/60	50	PAF	108.9 ± 22.6 vs. 123.6 ± 27.1; ()	15.6 ± 5.6 vs. 31.6 ± 9.9 ()	0.3[IQR 0–6] vs. 9.5[IQR 7.0–12.3] ()	—	62 vs. 78 ()	11.7 vs. 26.7 () (1 year)	PVI ± SVCI
Yazaki et al. [32]	64/32	50	PAF	115 ± 32 vs. 150 ± 57 ()	10±3 vs. 24 ± 6 ()	12 ± 9 vs. 13 ± 6 ()	—	—	28.1 vs. 34.4 () (10 months)	PVI ± CTI
Yavin et al. [33]	224/112	45–50	PAF and PsAF	—	17.2[median 17.5; range 14.6 to 29.2] vs. 31.1 [median31; range 24.6 to 70.1] ()	—	90.2 vs. 83.0 ()	—	—	PVI ± CTI ± linear ablation
Shin et al. [34]	150/50	50	PAF and PsAF	108.7 ± 23.1 vs. 135.6 ± 29.5 vs. 161.9 ± 37.9 (30 W vs. 40 W vs. 50 W) ()	38.2 ± 14.8 vs. 52.3 ± 21.5 vs. 73.1 ± 30.5 (30 W vs. 40 W  vs. 50 W); ()	9.7 ± 4.1 vs. 11.0 ± 3.0 vs. 12.5 ± 3.6 (30 W vs. 40 W vs. 50 W) ()		14.0 vs. 10.0 vs. 16.0 (30 W vs. 40 W vs. 50 W) ()	14.0 vs. 16.0 vs. 18.0 () (1 year)	PVI ± CTI ± linear ablation

AF: atrial fibrillation; CFAE: complex fractionated atrial electrograms; CAT: conventional ablation therapy; CTI: cavotricuspid isthmus; HPSD: high-power short-duration; IQR: interquartile range; PAF: paroxysmal atrial fibrillation; PsAF: persistent atrial fibrillation; PV: pulmonary vein; PVI: pulmonary vein isolation; RF: radiofrequency; SVCI: superior vena cava ablation.